RU2751253C1 - Противораковые вакцины, нацеленные на сурвивин, и их применения - Google Patents

Противораковые вакцины, нацеленные на сурвивин, и их применения Download PDF

Info

Publication number
RU2751253C1
RU2751253C1 RU2020122872A RU2020122872A RU2751253C1 RU 2751253 C1 RU2751253 C1 RU 2751253C1 RU 2020122872 A RU2020122872 A RU 2020122872A RU 2020122872 A RU2020122872 A RU 2020122872A RU 2751253 C1 RU2751253 C1 RU 2751253C1
Authority
RU
Russia
Prior art keywords
survivin
nucleic acid
antigen
seq
vaccine
Prior art date
Application number
RU2020122872A
Other languages
English (en)
Russian (ru)
Inventor
Цзянь Янь
Анна СЛАГЕР
Брэдли ГАРМАН
Нил КУЧ
Original Assignee
Иновио Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иновио Фармасьютикалз, Инк. filed Critical Иновио Фармасьютикалз, Инк.
Application granted granted Critical
Publication of RU2751253C1 publication Critical patent/RU2751253C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2020122872A 2017-12-13 2018-12-13 Противораковые вакцины, нацеленные на сурвивин, и их применения RU2751253C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762598267P 2017-12-13 2017-12-13
US62/598,267 2017-12-13
PCT/US2018/065529 WO2019118766A2 (en) 2017-12-13 2018-12-13 Cancer vaccines targeting survivin and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021117812A Division RU2776949C2 (ru) 2017-12-13 2018-12-13 Противораковые вакцины, нацеленные на сурвивин, и их применения

Publications (1)

Publication Number Publication Date
RU2751253C1 true RU2751253C1 (ru) 2021-07-12

Family

ID=66734396

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020122872A RU2751253C1 (ru) 2017-12-13 2018-12-13 Противораковые вакцины, нацеленные на сурвивин, и их применения

Country Status (11)

Country Link
US (2) US12064473B2 (https=)
EP (1) EP3723793A4 (https=)
JP (3) JP7385569B2 (https=)
KR (2) KR102648079B1 (https=)
CN (1) CN111479583A (https=)
AU (2) AU2018383664B2 (https=)
BR (1) BR112020011820A2 (https=)
CA (1) CA3083534A1 (https=)
MX (2) MX2020006285A (https=)
RU (1) RU2751253C1 (https=)
WO (1) WO2019118766A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102648079B1 (ko) * 2017-12-13 2024-03-18 이노비오 파마수티컬즈, 인크. 서바이빈을 표적으로 하는 암 백신 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151672A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of oncology-related proteins and peptides
WO2016179573A1 (en) * 2015-05-07 2016-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Variant survivin vaccine for treatment of cancer
US20160331844A1 (en) * 2015-04-22 2016-11-17 Curevac Ag Rna containing composition for treatment of tumor diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1152402A (en) 2000-10-04 2002-04-15 Univ Pennsylvania Highly expressible genes
US20110223187A1 (en) * 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
DK3122375T3 (da) * 2014-03-28 2021-05-25 Univ Washington Through Its Center For Commercialization Vacciner mod bryst- og ovariecancer
US20180305702A1 (en) * 2015-09-15 2018-10-25 Advaxis, Inc. Listeria-Based Immunogenic Compositions And Methods Of Use Thereof in Cancer Prevention And Treatment
KR102648079B1 (ko) * 2017-12-13 2024-03-18 이노비오 파마수티컬즈, 인크. 서바이빈을 표적으로 하는 암 백신 및 이의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151672A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of oncology-related proteins and peptides
US20160331844A1 (en) * 2015-04-22 2016-11-17 Curevac Ag Rna containing composition for treatment of tumor diseases
WO2016179573A1 (en) * 2015-05-07 2016-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Variant survivin vaccine for treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
СЕЛЕДЦОВ В.И. Ксеновакцино-терапия в лечении злокачественных заболеваний, Сибирский онкологический журнал, 2010, N 3 (39), с. 48-57. *

Also Published As

Publication number Publication date
JP2023155245A (ja) 2023-10-20
KR20240038139A (ko) 2024-03-22
AU2024264712A1 (en) 2024-12-05
JP7385569B2 (ja) 2023-11-22
KR102648079B1 (ko) 2024-03-18
EP3723793A4 (en) 2022-01-19
CN111479583A (zh) 2020-07-31
AU2018383664A1 (en) 2020-07-16
JP7659599B2 (ja) 2025-04-09
WO2019118766A3 (en) 2019-09-19
MX2020006285A (es) 2020-09-17
US20240358809A1 (en) 2024-10-31
BR112020011820A2 (pt) 2020-11-17
EP3723793A2 (en) 2020-10-21
US12064473B2 (en) 2024-08-20
RU2021117812A (ru) 2021-07-26
WO2019118766A2 (en) 2019-06-20
JP2025092647A (ja) 2025-06-19
KR20200096957A (ko) 2020-08-14
AU2018383664B2 (en) 2024-12-05
CA3083534A1 (en) 2019-06-20
US20190175707A1 (en) 2019-06-13
MX2025004799A (es) 2025-05-02
RU2021117812A3 (https=) 2021-11-08
JP2021506265A (ja) 2021-02-22

Similar Documents

Publication Publication Date Title
RU2748903C1 (ru) Противораковые вакцины, нацеленные на prame, и их применения
US20240358809A1 (en) Cancer vaccines targeting survivin and uses thereof
RU2776949C2 (ru) Противораковые вакцины, нацеленные на сурвивин, и их применения
RU2759681C1 (ru) Противораковые вакцины, нацеленные на boris, и способы их применения
US11986517B2 (en) Cancer vaccines targeting mesothelin and uses thereof
RU2799786C2 (ru) Противораковые вакцины, нацеленные на boris, и способы их применения
RU2830879C2 (ru) Мезотелин-нацеленные вакцины от рака и их применение